- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02721485
Crystalloid FLUID Choices for Resuscitation of Hospital Patients (FLUID)
Crystalloid FLUID Choices for Resuscitation of Hospital Patients: A Pragmatic Cluster Cross Over Pilot Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Other than the administration of oxygen, crystalloid resuscitation fluids are the most common intervention administered to the majority of hospitalized patients. These fluids may be used as a life saving measure to re-establish hemodynamic stability, for rehydration, and to replace losses and maintain intravascular volume in the surgical setting. In the province of Ontario alone, approximately 1 million patients per year will receive one or both of these resuscitation fluids during their hospital admission. The two most common usual care resuscitation crystalloid fluids are Normal Saline and Ringer's Lactate and until recently there was no evidence to suggest that one crystalloid fluid was clinically superior to the other. However, the safety of Normal Saline is now being questioned due to its high chloride content and its association with the development of hyperchloremic metabolic acidosis. Studies in healthy volunteers and observational studies in the critically ill and surgical patient populations have associated saline with an increased risk of acute renal injury and requirement for dialysis, post-operative infections, death and increased resource and blood transfusion use. The evidence base is currently weak given that the majority of studies are observational and suffer from methodological weaknesses including confounding by indication, selection bias, and inability to disentangle the effects of a specific fluid due to interaction of co-interventions administered. As such, several authors and editorials have called for adequately powered randomized controlled trials with clinically relevant outcomes to determine if Ringer's Lactate is indeed superior to Normal Saline for resuscitation.
Given their widespread use, small differences in clinical outcomes between crystalloid resuscitation fluids are highly relevant. Furthermore, small absolute differences in important clinical outcomes translate into significant savings to hospitals and the health care system. To illustrate, if death and hospital re-admissions were each reduced by an absolute 0.5%, this would translate to approximately 2500 lives saved and savings of 10 million dollars to the Ontario health care system. Hence, in collaboration with the Canadian Critical Care Trials Group, the Crystalloid FLUID Choices for Hospitalized Patients (FLUID) trial will examine whether Ringer's Lactate as compared to Normal Saline reduces clinically important outcomes such as death, and hospital re-admissions - outcomes that are particularly relevant to hospitals and the health care system. This proposal is a large pragmatic cluster cross-over comparative effectiveness trial that will be conducted in both academic and community centres in Ontario. It will involve waivers of consent and a novel design making use of provincially available health administrative data through the Institute of Clinical Evaluative Sciences (ICES) to facilitate all data collected in the trial. The trial will answer this fundamental fluid resuscitation question with much less cost in comparison to an individual patient randomized controlled trial. It will help build expertise and capacity for future trials of similar design in the province of Ontario and throughout Canada. However, prior to embarking on a large-scale trial, it is imperative to conduct a pilot trial to determine feasibility and optimize the trial design.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ontario
-
Hamilton, Ontario, Canada, L8L 2X2
- Hamilton General Hospital
-
Ottawa, Ontario, Canada, K1H 8L6
- The Ottawa Hospital General Campus
-
Ottawa, Ontario, Canada, 1053 Carling Ave
- Ottawa Hospital Civic Campus
-
Ottawa, Ontario, Canada, K2H 8P4
- Queensway Carleton Hosptial
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- All patients admitted to the participating hospitals for the first time in the last 90 days (index admission) over the duration of the study period.
Exclusion Criteria:
- Neonates (< 30 days)
- Physicians may also opt out of the use of the allocated study fluid for individual patients if there is a strong preference to do so.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Normal Saline
Half of the hospitals will be allocated to start the 90-day test period using Normal Saline administered as 500 or 1000 ml boluses or infusions as specified by the treating physicians.
After a 1 week run out, half of participating hospitals will have up to 2 weeks to switch out stock then will be crossed over to using Ringer's Lactate following a 1 week run in as 500 or 1000 ml boluses or infusions as specified by the treating physicians for the final 90-day test period.
|
After a 1 week run in half of participating hospitals will be crossed over to using Ringer's Lactate as 500 or 1000 ml boluses or infusions as specified by the treating physicians for the second 90-day test period.
|
Other: Ringer's Lactate
Half of the hospitals will be allocated to start the 90-day test period using Ringer's Lactate administered as 500 or 1000 ml boluses or infusions as specified by the treating physicians.
After a 1 week run out, half of participating hospitals will have up to 2 weeks to switch out stock then will be crossed over to using Normal Saline following a 1 week run in as 500 or 1000 ml boluses or infusions as specified by the treating physicians in for the final 90-day test period.
|
After a 1 week run in half of participating hospitals will be crossed over to using Normal Saline as 500 or 1000 ml boluses or infusions as specified by the treating physicians for the final 90-day test period.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Feasibility: adherence to protocol
Time Frame: Up to six months
|
Compliance defined as at least 80% of the prescribed study fluid being administered in the participating hospitals over the 2, 3-month study periods.
|
Up to six months
|
Feasibility: time to research ethics board approval
Time Frame: Up to three months
|
Compliance defined as taking no longer than 3 months to achieve
|
Up to three months
|
Feasibility: readiness to initiate protocol
Time Frame: Up to three months
|
Compliance defined as taking no longer than 3 months after ethics approval
|
Up to three months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Lauralyn McIntyre, MD MSc, Ottawa Hospital Research Institute
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 20150619-01H
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fluid Therapy
-
Nordsjaellands HospitalRigshospitalet, Denmark; University of CopenhagenRecruitingFluid Therapy | Fluid OverloadDenmark
-
Centre Hospitalier Universitaire, AmiensRecruitingFluid Therapy | Pharmacodynamics | Fluid Responsiveness | Fluid Challenge | Intravenous FluidsFrance
-
Uppsala UniversityCompletedFluid Therapy | Fluid Overload | Critical CareSweden
-
Erasme University HospitalUnknownFluid Therapy | Fluid and Electrolyte ImbalanceBelgium
-
Assiut UniversityCompleted
-
Rajiv Gandhi Cancer Institute & Research Center...Completed
-
Sociedad Española de Anestesiología, Reanimación...Hospital Clinic of Barcelona; Hospital Universitario La Fe; Hospital Universitario... and other collaboratorsUnknown
-
Bakirkoy Dr. Sadi Konuk Research and Training HospitalWithdrawnHemodynamic Monitoring | Fluid Management | Goal-Directed Fluid TherapyTurkey
-
Beijing Anzhen HospitalNot yet recruitingFluid Therapy | Microcirculation
Clinical Trials on Ringer's Lactate
-
University of CalgaryNot yet recruitingPost-ERCP Acute Pancreatitis
-
Paraskevi MatsotaCompleted
-
Ottawa Hospital Research InstituteCompleted
-
University of Sao PauloCompletedHip Replacement ArthroplastyBrazil
-
Alexandria UniversityCompletedNausea and Vomiting, PostoperativeEgypt
-
Innogene Kalbiotech Pte. LtdCompleted
-
MetroHealth Medical CenterCompletedFetus or Neonate Affected by Maternal Epidural Anesthesia During Labor and DeliveryUnited States
-
St. Boniface HospitalUniversity of ManitobaUnknown
-
Insel Gruppe AG, University Hospital BernRecruitingCritical Illness | Subarachnoid Hemorrhage | Sodium Disorder | Infusion FluidSwitzerland
-
Innogene Kalbiotech Pte. LtdCompletedLow Cardiac OutputIndonesia